Le Lézard
Classified in: Health
Subjects: CCA, PET, FVT

IDEXX Laboratories to Release 2017 Third Quarter Financial Results



WESTBROOK, Maine, Oct. 5, 2017 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2017 third quarter financial results for Tuesday, October 31, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-230-1092 or 1-612-288-0340 and reference confirmation code 431383. Replay of the conference call will be available through Tuesday, November 7, 2017 by dialing 1-800-475-6701 or 1-320-365-3844 and referencing replay code 431383.

IDEXX Laboratories, Inc. logo. (PRNewsFoto/IDEXX Laboratories, Inc.)

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a member of the S&P 500® index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 7,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit: www.idexx.com.

Contact:
Investor Relations:
Kerry Bennett   
207-556-8155

SOURCE IDEXX Laboratories, Inc.


These press releases may also interest you

at 10:00
COLORADO SPRINGS, Colo., June 23, 2018 /PRNewswire-PRWeb/ -- Dr. John R. Burroughs, the Medical Director of Springs Aesthetics, is proud to be the first medical spa in Colorado Springs to offer vFit PLUS for sale. This revolutionary device promotes...

at 10:00
Fractyl Laboratories Inc. (Fractyl) today announced the presentation of breakthrough research providing the first clear mechanistic link between modern diets and their causal effect on the pandemics of insulin resistance, obesity, and metabolic...

at 10:00
Findings from CONFIRM ? a large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus Toujeo® (insulin glargine U300) ? will be presented on Monday,...

at 10:00
Boehringer Ingelheim and Eli Lilly and Company today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes Association (ADA) Scientific Sessions®. Results include a post-hoc...

at 10:00
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new findings from two real-world studies comparing sodium glucose co-transporter-2 inhibitor (SGLT2i) INVOKANA® (canagliflozin) and glucagon-like peptide-1 receptor agonists...

at 10:00
Eli Lilly and Company's ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog®. URLi is...




News published on 5 october 2017 at 14:00 and distributed by: